Zimmer Partners LP increased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 24.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,900 shares of the biotechnology company's stock after buying an additional 18,900 shares during the period. Zimmer Partners LP owned 0.16% of Ascendis Pharma A/S worth $13,340,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in Ascendis Pharma A/S during the 4th quarter worth about $28,000. Jones Financial Companies Lllp lifted its position in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after buying an additional 197 shares in the last quarter. Blue Trust Inc. lifted its position in Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after buying an additional 328 shares in the last quarter. Quarry LP acquired a new position in Ascendis Pharma A/S during the 4th quarter worth about $96,000. Finally, Tower Research Capital LLC TRC lifted its position in Ascendis Pharma A/S by 195.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after buying an additional 664 shares in the last quarter.
Ascendis Pharma A/S Price Performance
Shares of NASDAQ:ASND opened at $160.33 on Tuesday. The company has a market capitalization of $9.78 billion, a price-to-earnings ratio of -22.58 and a beta of 0.41. The firm's 50 day simple moving average is $157.35 and its 200 day simple moving average is $142.88. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $183.00.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million for the quarter, compared to analyst estimates of $98.56 million. Equities research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.
Wall Street Analyst Weigh In
ASND has been the topic of several research reports. The Goldman Sachs Group upped their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Evercore ISI upped their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Wedbush upped their target price on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Morgan Stanley upgraded shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $180.00 to $250.00 in a research report on Monday, May 5th. Finally, JPMorgan Chase & Co. upped their target price on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an "overweight" rating in a research report on Friday, May 2nd. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $216.07.
Read Our Latest Stock Analysis on ASND
Ascendis Pharma A/S Profile
(
Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Featured Stories
Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
